-
News Express | Belzutifan, an Oral HIF-2α Inhibitor, for Treating VHL-Associated Congenital Polycythemia
The “News Express” column aims to bridge the gap between cutting-edge research and clinical practice, enabling hematology enthusiasts and professionals to quickly grasp industry trends, spark innovative thinking, and broaden their professional horizons. Hematology News carefully curates the latest hematological research findings from top global journals. Each selected article represents a fusion of science and…
-
Dr. Bing Xu: Understanding and Conquering IVLBCL—Progress in Diagnosis and Treatment | 2024 Northern Hematology and Oncology Immunotherapy Conference
Intravascular large B-cell lymphoma (IVLBCL) is a rare form of non-Hodgkin lymphoma with atypical clinical presentations, leading to high rates of misdiagnosis and missed diagnosis in clinical practice. There is an urgent need to improve the current status of diagnosis and treatment. Recently, the “2024 Northern Hematology and Oncology Immunotherapy Conference,” hosted by the Tianjin…
-
Dr. Jun Shi: Ongoing Exploration to Optimize First-Line Treatment for Non-Gastric MALT Lymphoma | 2024 Northern Hematology and Oncology Immunotherapy
While radiotherapy is the recommended first-line treatment for mucosa-associated lymphoid tissue (MALT) lymphoma, for certain non-gastric MALT lymphomas in specific locations, radiotherapy may result in significant side effects that can affect patients’ quality of life. Recently, the “2024 Northern Hematology and Oncology Immunotherapy Conference,” hosted by the Tianjin Society of Hematology and Regenerative Medicine, was…
-
Dr. Sujun Zheng: From Hepatitis to Liver Cancer – Exploring Comprehensive Management of Liver Diseases
HBV infection is a major cause of chronic hepatitis B (CHB), cirrhosis, liver failure, and hepatocellular carcinoma. Despite the development of new drugs and advancements in antiviral therapy, a complete cure for CHB remains a clinical challenge. The burden of liver disease in China is still heavy, and the implementation of high-quality liver disease management…
-
Showcasing Chinese Wisdom on the International Stage: The 25th International AIDS Conference, China Special Session
From July 22-26, 2024, the 25th International AIDS Conference (AIDS 2024) was held in Munich, Germany. As a key player in the global fight against AIDS, China has consistently made significant contributions. At this conference, the China Special Session, titled “Ending AIDS in China: Challenges and Strategies,” was jointly organized by the Chinese Association of…
-
Voice of China in AIDS Research丨Dr. Fujie Zhang’s Team: Efficacy of Long-term Antiretroviral Therapy in Chinese Children and Adolescents with HIV
From July 22-26, 2024, the 25th International AIDS Conference took place in Munich, Germany, gathering 15,000 professionals and advocates from around the world to discuss the latest advancements and future challenges in AIDS prevention and treatment. At the conference, Dr. Hanxi Zhang from Dr. Fujie Zhang’s team at Beijing Ditan Hospital presented a multicenter, prospective,…
-
2024 CUDA丨Dr. Xiongjun Ye: Mastering the Characteristics and Approaches of Robot-Assisted Partial Nephrectomy, Clarifying the Path to Optimization
From August 8th to 11th, 2024, the Annual Meeting of the Urology Physicians Branch of the Chinese Medical Doctor Association (CUDA) was held in Xi’an. Organized by the Chinese Medical Doctor Association and the Urology Physicians Branch, and hosted by Xijing Hospital of the Air Force Medical University, with support from the Urology Physicians Branch…
-
JAMA Oncol | Tumor Mutational Burden and Its Response to Immune Checkpoint Inhibitors in Metastatic Castration-Resistant Prostate Cancer
This study explored the relationship between tumor mutational burden (TMB) status and the efficacy and prognosis of mCRPC patients treated with the immune checkpoint inhibitor pembrolizumab. The study retrospectively analyzed…
Connecting Medical Expertise through Media